SLC12A2 and brain disorder: NKCC1 thus represents an attractive therapeutic target for the treatment of various brain disorders where aberrantly elevated NKCC1 activity and intracellular [Cl−] in neurons lead to attenuated inhibitory synaptic transmission that critically depends on an inward directed [Cl−] electrochemical gradient (Kaila et al, 2014; Savardi et al, 2021).